Search results
Jan 22, 2019 · The first settlement, approved on January 16, 2019, by U.S. District Judge Paul A. Crotty and unsealed today, requires WALGREENS to pay $209.2 million to resolve allegations that it improperly billed Medicare, Medicaid, and other federal healthcare programs for hundreds of thousands of insulin pens it knowingly dispensed to program ...
Jan 23, 2019 · NEW YORK (Reuters) - Walgreens Boots Alliance Inc will pay $269.2 million to settle two whistleblower lawsuits accusing it of civil fraud for overbilling federal healthcare programs over a...
Jan 22, 2019 · NEW YORK, Jan 22 (Reuters) - Walgreens Boots Alliance Inc will pay $269.2 million to settle two whistleblower lawsuits accusing it of civil fraud for overbilling federal healthcare programs...
Jan 22, 2019 · Manhattan U.S. Attorney Announces $269.2 Million Recovery From Walgreens In Two Civil Healthcare Fraud Settlements. Geoffrey S. Berman, the United States Attorney for the Southern District of New York, Gregory E. Demske, Chief Counsel to the Inspector General of the U.S. Department of Health and Human Services ("HHS-OIG"), Scott J. Lampert ...
Jan 23, 2019 · The pharmacy chain will pay $209.2 million to resolve claims it improperly billed Medicare, Medicaid and other federal programs from 2006 to 2017 for hundreds of thousands of insulin pens it dispensed to patients it knew did not need them.
Jan 23, 2019 · Walgreens Boots Alliance has agreed to pay more than $269 million to settle allegations it took advantage of Medicare and Medicaid, the U.S. Department of Justice said Tuesday.
The first claim alleged that Walgreens billed federal health care programs, including Medicare and Medicaid, for distributing insulin pens to hundreds of thousands of individuals that did not require them. That settlement resulted in a $209.2 million payment from the company.
